The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Richard L. Piekarz

Departmentof Health and Human Services

Center for Cancer Researchand Cancer Therapy EvaluationProgram

National Cancer Institute

National Institutes of Health



Name/email consistency: high



  • Departmentof Health and Human Services, Center for Cancer Researchand Cancer Therapy EvaluationProgram, National Cancer Institute, National Institutes of Health, USA. 2006 - 2009
  • Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute/NIH, MSC 1903, USA. 2004 - 2007
  • Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, USA. 2001


  1. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Piekarz, R.L., Frye, R., Turner, M., Wright, J.J., Allen, S.L., Kirschbaum, M.H., Zain, J., Prince, H.M., Leonard, J.P., Geskin, L.J., Reeder, C., Joske, D., Figg, W.D., Gardner, E.R., Steinberg, S.M., Jaffe, E.S., Stetler-Stevenson, M., Lade, S., Fojo, A.T., Bates, S.E. J. Clin. Oncol. (2009) [Pubmed]
  2. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Piekarz, R.L., Sackett, D.L., Bates, S.E. Cancer. J (2007) [Pubmed]
  3. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Piekarz, R.L., Frye, A.R., Wright, J.J., Steinberg, S.M., Liewehr, D.J., Rosing, D.R., Sachdev, V., Fojo, T., Bates, S.E. Clin. Cancer Res. (2006) [Pubmed]
  4. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Piekarz, R.L., Robey, R.W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A.H., Torrico, S., Bates, S.E. Blood (2004) [Pubmed]
  5. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Piekarz, R.L., Robey, R., Sandor, V., Bakke, S., Wilson, W.H., Dahmoush, L., Kingma, D.M., Turner, M.L., Altemus, R., Bates, S.E. Blood (2001) [Pubmed]
WikiGenes - Universities